Handok한독
002390 · KOSPI · ₩002390 · 한독
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
With these assumptions the model gives no positive value.
- Enterprise value
- ₩151B
- Equity value
- −₩109B
- WACC
- 4.8%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Why the model and the price differ
The model gives no positive value at these assumptions. What we can see:
- To match today's price of ₩8,320, the model needs an operating margin of 4.0% every year (it uses 2.4%).
Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.
Bear / Base / Bull
- Bear
- —
- Base
- —
- Bull
- ₩35,773
- +330.0%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (2.4%).
Revenue growth
- -0.5%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-0.5% a year, annual reports), fading to 3% by year 5.
- 0.4%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-0.5% a year, annual reports), fading to 3% by year 5.
- 1.2%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-0.5% a year, annual reports), fading to 3% by year 5.
- 2.1%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-0.5% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-0.5% a year, annual reports), fading to 3% by year 5.
Business
- 2.4%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 3.1%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).
- 3.9%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).
- 31.3%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.03%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-27.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.53%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩561B
- Net debt (borrowings and leases − cash and deposits)
- ₩353B
- + Stakes and investments
- ₩95B
- Associates, long-term financial assets and deposits (book value)
- − Minority interests
- ₩1.8B
- Shares
- 13,763,533
- Share price
- ₩8,320
- Market cap
- ₩115B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2023 | FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩523B | ₩507B | ₩535B | ₩558B | ₩560B | ₩567B | ₩579B | ₩596B |
| Growth | −3.9% | −2.9% | 5.5% | −0.5% | 0.4% | 1.2% | 2.1% | 3.0% |
| EBIT | ₩13B | ₩539M | ₩3.3B | ₩13B | ₩13B | ₩14B | ₩14B | ₩14B |
| EBIT margin | 2.4% | 0.1% | 0.6% | 2.4% | 2.4% | 2.4% | 2.4% | 2.4% |
| After-tax EBIT | ₩9.1B | ₩390M | ₩2.4B | ₩9.7B | ₩9.7B | ₩9.9B | ₩10B | ₩10B |
| + Depreciation | — | — | — | ₩17B | ₩17B | ₩18B | ₩18B | ₩18B |
| − Capital spending | ₩26B | ₩19B | ₩16B | ₩22B | ₩22B | ₩22B | ₩23B | ₩23B |
| − Working capital | −₩7B | ₩10B | ₩14B | −₩878M | ₩699M | ₩2.1B | ₩3.7B | ₩5.4B |
| Free cash flow | — | — | — | ₩6.1B | ₩4.6B | ₩3.2B | ₩1.7B | ₩169M |
| Discount factor | — | — | — | 0.954 | 0.910 | 0.868 | 0.828 | 0.790 |
| Present value | — | — | — | ₩5.8B | ₩4.2B | ₩2.8B | ₩1.4B | ₩134M |
Terminal value ₩173B, worth ₩137B today: 91% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Cross-check: what the market has paid before
For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:
| Low | Typical | High | |
|---|---|---|---|
| Price / book (book value ₩18,403 a share)Now 0.45× | ₩8,9810.49× | ₩10,5970.58× | ₩13,1430.71× |
Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 3.8% | — | — | — | ₩163 | ₩4,223 |
| 4.3% | — | — | — | — | — |
| 4.8% | — | — | — | — | — |
| 5.3% | — | — | — | — | — |
| 5.8% | — | — | — | — | — |
Now (TTM)
- Market cap
- ₩115B
- Enterprise value
- ₩466B
- P/E
- —
- P/B
- 0.5×
- P/S
- 0.2×
- EV/EBITDA
- —
- Dividend yield
- 2.4%
Over time (at each year end)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Price | ₩11,200 | ₩12,050 | ₩14,300 | ₩16,750 | ₩22,800 |
| Market cap | ₩154B | ₩166B | ₩197B | ₩231B | ₩314B |
| P/E | — | — | — | 21.6× | 95.2× |
| P/B | 0.6× | 0.6× | 0.6× | 0.6× | 0.8× |
| P/S | 0.3× | 0.3× | 0.4× | 0.4× | 0.6× |
| EV/EBITDA | — | — | — | — | — |
| Dividend yield | 1.8% | 1.7% | — | — | — |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| Handok | — | 0.5× | 0.2× | — | 2.4% |
| Samsung Biologics | 32.1× | 7.6× | 14.0× | — | 0.0% |
| Celltrion | 27.8× | 2.4× | 8.9× | — | 0.0% |
| Alteogen | 78.8× | 28.4× | 59.9× | — | 0.1% |
| Yuhan | 24.8× | 2.5× | 2.6× | 32.5× | 0.8% |
| SK biopharmaceuticals | 14.6× | 5.7× | 6.8× | — | 0.0% |
| HLB | — | 15.4× | 54.6× | — | 0.0% |
| Similar companies (median) | 27.8× | 6.7× | 11.5× | 32.5× | 0.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: Handok / 한독 / 002390 / KRX:002390
Source: KRX statistical information